The Nottingham Prognostic Index Plus test for breast cancer management
NIHR HSRIC
Record ID 32016000469
English
Authors' objectives:
The Nottingham Prognostic Index Plus test (NPI+) is a biomarker-based test developed by the University of Nottingham to support individualised clinical decision making in breast cancer treatment. The immunohistochemistry test, which measures protein levels in the tumour tissue, is intended to be used in women aged 18-70 years with primary operative breast cancer at either core needle biopsy stage or post-surgery, pre-adjuvant therapy.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/the-nottingham-prognostic-index-plus-test-for-breast-cancer-management/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Breast Neoplasms
- Receptors, Estrogen
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.